MedTrace Logo

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

NCT04827563 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-03-04

No results posted yet for this study

Summary

This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.

Conditions

Interventions

DEVICE

EndoPAT

An FDA approved device to test the health of a patient's blood vessels, which involves putting an oxygen probe on the participant's finger.

DEVICE

Blood Pressure Cuff

A device used to conduct blood pressure monitoring using a home blood pressure cuff that participant wears for 24 hours.

DIAGNOSTIC_TEST

Echocardiogram

A test used to conduct an ultrasound of participant's heart.

OTHER

Quality of Life Assessment

A survey that will be given to participants to report their quality of life and symptoms related to multiple myeloma.

OTHER

Blood Tests

Routinely collected for all participants who begin carfilzomib treatment.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Jeanne DeCara, MD · University of Chicago - Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2025-09-08
Completion
2025-09-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04827563 on ClinicalTrials.gov